| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefit VCAR33ALLO demons...
PureTech Health (NASDAQ:PRTC) reported quarterly losses of $(0.15) per share. This is a 66.67 percent decrease over losses of $...
The Company is offering to purchase up to 33,500,000 Ordinary Shares (including Ordinary Shares represented by ADSs) represen...
PureTech Health (NASDAQ:PRTC) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.9...
